COVID-19: CMIC starts Avigan clinical trial / manufacturing: Phase III trial CRO / CDMO
COVID-19: CMIC
Contributing to early provision to patients with new-type coronavirus infection
CMIC Holdings:
In the COVID-19 patient target / Phase III trial, we are providing clinical trial services for Avigan as a CRO (contract drug development agency).
In addition, as a CDMO (contract organization for drug formulation development and manufacturing), we have become “supporting the manufacture of Abigan”.
The CMIC Group supports clinical development at its affiliated company, CMIC CRO.
In addition, CMIC CMO will manufacture “Abigan” at its main domestic factory.
CMIC Group
https://www.cmicgroup.com/news/20200423
CMIC Supports Avigan Production for Potential COVID-19 Treatment
CMIC Holdings Co., Ltd.
said its affiliate, CMIC Co., Ltd., a contract research organization (CRO) in Japan, is providing monitoring services for Avigan Tablet (favipiravir),
a product that Fujifilm Toyama Chemical Co., Ltd. gained approval in Japan for manufacture and sale as an influenza antiviral drug, phase III clinical trial in Japan
and will support for manufacturing the product as a contract development and manufacturing organization (CDMO).
Also, CMIC CMO Co., Ltd., a CDMO in Japan, will manufacture Avigan Tablet at their main plant to contribute to Fujifilm’s accelerated production schedule.